All In Biotech

Drug Trial Radar · NCT06633419

A Drug-Drug Interaction Study of Carbamazepine and Opevesostat (MK-5684) in Healthy Adult Male Participants (MK-5684-012)

A Phase 1, Open-Label, Fixed-Sequence Study to Evaluate the Effects of Multiple Doses of Carbamazepine on the Single-Dose Pharmacokinetics of MK-5684 in Healthy Adult Male Participants

Last checked: Nov 19, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

14

Actual

Start

Dec 18, 2024

Primary completion

Feb 12, 2025

Study completion May 13, 2025

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Oct 9, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic or PK study). Researchers will compare what happens to opevesostat in the body when it is given with and without another medicine called carbamazepine.

Conditions

  • Healthy

Interventions

  • OpevesostatDrug

    Administered via oral tablet per dosing regimen.

  • PrednisoneDrug

    Administered at a dose of 5 mg or 10 mg dependent on HRT dosing regimen via oral tablets.

  • Fludrocortisone acetateDrug

    Administered at a dose of 0.05 mg or 0.1 mg dependent on HRT dosing regimen via oral tablets.

  • CarbamazepineDrug

    Administered at a dose of 100 mg, 200 mg, or 300 mg BID dependent on dosing regimen via oral capsule (extended-release).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the concentration versus time curve from 0 to infinity after single dosing (AUC0-inf) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  2. Area under the concentration versus time curve from 0 to last quantifiable sample (AUC0-last) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  3. Area under the concentration versus time curve from 0 to hour 24 (AUC0-24) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 24 hours post-dose
  4. Maximum concentration (Cmax) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  5. Time to Maximum concentration (Tmax) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  6. Apparent terminal half-life (t1/2) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  7. Apparent Clearance (CL/F) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose
  8. Apparent volume of distribution during terminal phase (Vz/F) of opevesostat in plasmaTime frame: Predose, and at designated timepoints up to 96 hours post-dose

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Celerion ( Site 0001)

    Tempe, Arizona

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.